JP2022550734A - ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法 - Google Patents

ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法 Download PDF

Info

Publication number
JP2022550734A
JP2022550734A JP2022519057A JP2022519057A JP2022550734A JP 2022550734 A JP2022550734 A JP 2022550734A JP 2022519057 A JP2022519057 A JP 2022519057A JP 2022519057 A JP2022519057 A JP 2022519057A JP 2022550734 A JP2022550734 A JP 2022550734A
Authority
JP
Japan
Prior art keywords
patient
svhd
patients
udenafil
fontan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550734A5 (https=
Inventor
エル． イエーガー，ジェイムズ
デビッド ジェイ． ゴールドバーグ
エム． パリドン，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2022550734A publication Critical patent/JP2022550734A/ja
Publication of JP2022550734A5 publication Critical patent/JP2022550734A5/ja
Priority to JP2025063654A priority Critical patent/JP2025118624A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022519057A 2019-09-24 2020-05-12 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法 Pending JP2022550734A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063654A JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962905350P 2019-09-24 2019-09-24
US62/905,350 2019-09-24
US201962936497P 2019-11-16 2019-11-16
US62/936,497 2019-11-16
US202063023070P 2020-05-11 2020-05-11
US63/023,070 2020-05-11
PCT/US2020/032493 WO2021061203A1 (en) 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063654A Division JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Publications (2)

Publication Number Publication Date
JP2022550734A true JP2022550734A (ja) 2022-12-05
JP2022550734A5 JP2022550734A5 (https=) 2023-06-07

Family

ID=75167062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519057A Pending JP2022550734A (ja) 2019-09-24 2020-05-12 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
JP2025063654A Pending JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063654A Pending JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Country Status (7)

Country Link
US (1) US12576081B2 (https=)
EP (1) EP4041242A4 (https=)
JP (2) JP2022550734A (https=)
AU (1) AU2020356193A1 (https=)
CA (1) CA3155861A1 (https=)
MX (1) MX2022003593A (https=)
WO (1) WO2021061203A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3227475A1 (en) * 2021-07-26 2023-02-02 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
CN119072312A (zh) * 2021-12-20 2024-12-03 美智恩制药公司 用于改善运动表现的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128705A1 (en) * 2014-08-12 2016-02-18 Mezzion Pharma Co., Ltd. Methods of improving myocardial performance in fontan patients using udenafil compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
US7811244B2 (en) * 2004-03-23 2010-10-12 Georgia Tech Research Corp. Anatomical connection
PT1888074E (pt) 2005-06-10 2012-03-01 Dong A Pharm Co Ltd Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
JP2009509984A (ja) 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
WO2008151734A1 (en) 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128705A1 (en) * 2014-08-12 2016-02-18 Mezzion Pharma Co., Ltd. Methods of improving myocardial performance in fontan patients using udenafil compositions
JP2017524705A (ja) * 2014-08-12 2017-08-31 メジオン ファーマ カンパニー リミテッド ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOLDBERG, D.J. ET AL., CIRCULATION, vol. 123, JPN6024016564, 2011, pages 1185 - 1193, ISSN: 0005480527 *

Also Published As

Publication number Publication date
JP2025118624A (ja) 2025-08-13
AU2020356193A1 (en) 2022-05-19
CA3155861A1 (en) 2021-04-01
EP4041242A4 (en) 2023-10-18
US20240197736A1 (en) 2024-06-20
MX2022003593A (es) 2022-09-19
EP4041242A1 (en) 2022-08-17
US12576081B2 (en) 2026-03-17
WO2021061203A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
Guazzi et al. Long-term use of sildenafil in the therapeutic management of heart failure
US20250186448A1 (en) Formulations of udenafil
JP2024020187A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
JP2025118624A (ja) ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
Carrick-Ranson et al. Effects of aging and endurance exercise training on cardiorespiratory fitness and cardiac structure and function in healthy midlife and older women
CA2900526C (en) Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
JP2025504706A (ja) 運動機能を改善する方法および組成物
Goldberg et al. Results of the Fontan Udenafil exercise longitudinal (FUEL) trial
Nagumo et al. Effects of Atezolizumab plus Bevacizumab on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma
Posters The Pulse of Asia 2017 Taipei
Posters The Pulse of Asia 2017 Taipei

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408